Table 1. Patient demographics and operative and perioperative outcomes (n=3,000).
| Characteristic | Value | |
|---|---|---|
| Age (y) | 69.6±7.7 | |
| Comorbidities | ||
| Diabetes mellitus | 576 (19.2) | |
| Hypertension | 1,206 (40.2) | |
| Cardiovascular disease | 101 (3.4) | |
| Preoperative PSA level (ng/mL) | 2.8 (1.5–5.2) | |
| Total prostate volume (mL) | 67.7±3.4 | |
| Prostate transition zone volume (mL) | 39.0±26.2 | |
| IPSS | ||
| IPSS, storage symptom score | 7.9±3.4 | |
| IPSS, voiding symptom score | 11.4±5.2 | |
| IPSS, total score | 19.3±7.7 | |
| IPSS, QoL score | 3.9±1.1 | |
| OABSS questionnaire score | 6.3±3.4 | |
| Qmax (mL/s) | 9.4±4.8 | |
| Post-void residual volume (mL) | 51.0 (20.0–109.0) | |
| Operative outcomes | ||
| Total operation time (min) | 60.7±31.5 | |
| Enucleation time (min) | 37.9±17.9 | |
| Morcellation time (min) | 10.2±8.4 | |
| Extracted tissue volume (mL) | 24.0±20.9 | |
| Perioperative outcomes | ||
| Catheterization time (d) | 1.0 (1.0–1.0) | |
| Postoperative hospital stay (d) | 1.0 (1.0–1.0) | |
| Surgical pathology | ||
| Benign nodular hyperplasia | 2,836 (94.5) | |
| Incidental prostate adenocarcinoma | 162 (5.4) | |
| Incidental transitional cell carcinoma | 2 (0.1) | |
Values are presented as mean±standard deviation, number (%), or median (interquartile range).
PSA, prostate-specific antigen; IPSS, International Prostate Symptom Score; QoL, quality of life; OABSS, Overactive Bladder Symptom Score; Qmax, maximum flow rate.